Recombinant gonadotropins

Clinical Obstetrics and Gynecology

Volumn 46, Issue 2, 2003, Pages 298-316

  McClamrock, Howard D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; BUSERELIN ACETATE; CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADOTROPIN DERIVATIVE; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; RECOMBINANT HORMONE; THYROTROPIN; UROFOLLITROPIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FERTILIZATION IN VITRO; HORMONE STRUCTURE; HUMAN; IMMUNOREACTIVITY; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; PREGNANCY; REVIEW;

CHORIONIC GONADOTROPIN; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; PREGNANCY; RECOMBINANT PROTEINS;

EID: 0038488247     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200306000-00009     Document Type: Review

References (63)

1. Risquez F. Induction of follicular growth and ovulation with urinary and recombinant gonadotropins. Reproductive Biomedicine Online webpaper. July 16, 2001: Vol. 3, No. 1:54-72.
2. Pierce JG, Parsons TF, Glycoprotein hormones: structure and runction. Annu Rev Biochem. 1981;50:465-495.
3. Recombinant Human FSH Product Development Group. Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Hum Reprod Update. 1998;4:862-881.
4. Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil Steril. 1996;66:187-201.
5. Jameson JL, Kay TWH, Drust DS, et al. Hormonal regulation of gonadotropin gene expression. In: Gibori G, ed. Signaling mechanisms and gene expression in the ovary. Serono Symposia USA. New York: Springer-Verlag, 1991:11-22.
6. Howles CM. Genetic engineering of human FSH (Gonal-F). Hum Reprod Update. 1996;2:172-191.
7. Keene JL, Matzuk MM, Otani T, et al. Expression of biologically active human follitropin in Chinese hamster ovary cells. J Biol Chem. 1989;264:4769-4775.
8. Galway AB, Hseuh AJ, Keene JL, et al. In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. Endocrinology. 1990;126:93-100.
9. Hard K, Mekking A, Damm JB, et al. Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin expressed in Chinese hamster ovary cells. Eur J Biochem. 1990;193:263-271.
10. Loumaye E, Campbell R, Salat-Baroux J. Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians. Hum Reprod Update. 1995;1:188-199.
11. Hornnes P, Giroud D, Howles C, et al. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman. Fertil Steril. 1993;60:724-726.
12. Germond M, Dessole S, Senn A, et al. Successful in-vitro fertilization and embryo transfer after treatment with recombinant human FSH [letter]. Lancet. 1992;338:1170.
13. Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating ovarian follicular development before in vitro fertilization. Fertil Steril. 1995;63:77-86.
14. Out H, Mannaerts B, Driessen S, et al. A prospective, randomized, assessor-blind, multicenter study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum Reprod. 1995;10:2534-2540.
15. Hedon B, Out HJ, Hugues JN, et al. Efficacy and safety of recombinant FSH (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicenter trial. Hum Reprod. 1995;10:3102-3106.
16. Bergh C, Howles CM, Borg K, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod. 1997;12:2133-2139.
17. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod. 1999;14:2207-2215.
18. Frydman R, Howles CM, Truong F. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. Hum Reprod. 2000;15:520-525.
19. Lenton E, Soltan A, Hewitt, et al. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP). Hum Reprod. 2000;15:1021-1027.
20. Schats R, Sutter P, Bassil S, et al. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. Hum Reprod. 2000;15:1691-1697.
21. Raga F, Bonilla-Musoles F, Casan E, et al. Recombinant follicle stimulating hormone stimulation on poor responders with normal basal concentrations of follicle stimulating hormone and estradiol: improved reproductive outcome. Hum Reprod. 1999;14:1431-1434.
22. DePlacido G, Alviggi C, Mollo A, et al. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod. 2000;15:17-20.
23. Strehler E, Abt M, El-Danasouri I, et al. Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome. Fertil Steril. 2001;75:332-336.
24. Westergaard L, Erb K, Laursen S, et al. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2001;76:543-549.
25. Feigenbaum S, Miller P, Kaufmann R, et al. A new highly purified human-derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends. 2001;19:297-313.
26. Dickey R, Thornton M, Nichols J, et al. Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-β for in vitro fertilization: a prospective, randomized study. Fertil Steril. 2002;77:1202-1208.
27. The European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78:520-528.
28. Hoomans E, Andersen A, Loft A, et al. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed dose regimen in women undergoing ovarian stimulation. Hum Reprod. 1999;14:2442-2447.
29. Bergh C. Recombinant follicle stimulating hormone. Hum Reprod. 1999;14:1418-1419.
30. Meniru G. What are the clinical benefits of recombinant gonadotrophins? Hum Reprod. 1999;14:1409-1419
31. Camier B, the French multicenter trialists, Howles CM, et al. A multicenter, prospective, randomized study to compare a lowdose protocol versus conventional administration of recombinant human follicle stimulating hormone (Gonal-F) in normoresponder women undergoing IVF/ISCI. Hum Reprod. 1998;13 (Supplement, Abstract P-058):159.
32. Out H, Lindenbert S, Lis Mikkelsen A, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod. 1999;14:622-627.
33. Ng E, Yeung W, Ho P. Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomized double-blind study. Hong Kong Med J. 2000;6:368-374.
34. Out H, David I, Ron-El R, et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU or recombinant FSH in ICSI cycles. Hum Reprod. 2001;16:1104-1109.
35. Out H, Braat D, Lintsen B, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod. 2000;15:29-35.
36. Wikland M, Bergh C, Borg K, et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod. 2001;16:1676-1681.
37. Olijve W, De Boer W, Mulders JWM, et al. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod. 1996;2:371-382.
38. Horsman G, Talbot JA, McLoughlin JD, et al. A biologic, immunologic and physicochemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Hum Reprod. 2000;15:1898-1902
39. Tulppala M, Aho M, Tuuri T, et al. Comparison of two recombinant follicle-stimulating hormone preparations in invitro fertilizations: a randomized clinical study. Hum Reprod. 1999;14:2709-2715.
40. Brindsen P, Akagboso F, Gibbons L, et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2001;73:114-116.
41. Harlin J, Csemiczky, Wramsby H, et al. Recombinant follicle stimulating hormone in in-vitro fertilization treatment: clinical experience with follitropin alpha and follitropin beta. Hum Reprod. 2000;15:239-244.
42. Ola B, Papaioannou S, Afnan M, et al. Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta-analysis. Fertil Steril. 2001;75:1106-1110.
43. Silverberg K, Daya S, Auray J, et al. Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertil Steril. 2002;77:107-113.
44. The European Recombinant Human Chorionic Gonadotrophin Study Group. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment-recombinant HCG versus urinary HCG. Hum Reprod. 2000;15:1446-1451.
45. Agrawal R, West C, Conway G, et al. Pregnancy after treatment with three recombinant gonadotropins. Lancet. 1997;349:29-30.
46. Penarrubia J, Balasch J, Fabregues F, et al. Recurrent empty follicle syndrome successfully treated with recombinant human chorionic gonadotrophin. Hum Reprod. 1999;14:1703-1706.
47. Driscoll G, Tyler J, Hangan J, et al. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for induction oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod. 2000;15:1305-1310.
48. The International Recombinant Human Chorionic Gonadotropin Study Group. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril. 2001;75:1111-1118.
49. Chang P, Kenley S, Burns T, et al. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertil Steril. 2001;76:67-74.
50. The European Recombinant LH Study Group. Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter, double-blind study. J Clin Endocrinol Metab. 2001;86:2607-2618.
51. The European Recombinant LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83:1507-1514.
52. Sills E, Levy D, Moomjy M, et al. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in invitro fertilization. Hum Reprod. 1999;19:2230-2235.
53. Balasch J, Vidal E, Penarrubia J, et al. Suppression of LH during ovarian stimulation: analyzing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod. 2001;60:1636-1643.
54. Esposito M, Barnhard K, Coutifaris C, et al. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril. 2001;75:519-524.
55. Westergaard LG, Laursen SB, Yding Andersen C. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003-1008.
56. Shoham Z, Balen A, Patel A, et al. Results of ovarian induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril. 1991;56:1048-1053.
57. Balasch J, Miro F, Burzacol, et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod. 1995;10:1678-1683.
58. Schoot DC, Harlin J, Shoham Z, et al. Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women. Hum Reprod. 1994;9:1237-1242.
59. Kousta E, White DM, Piazzi A, et al. Successful induction of ovulation and completed pregnancy using recombinant luteinizing hormone and follicle stimulating hormone in a woman with Kallman's syndrome. Hum Reprod. 1996;11:70-71.
60. Hull M, Corrigan E, Piazzi A, et al. Recombinant human luteinizing hormone: an effective new gonadotropin preparation. Lancet. 1994;344:334-335.
61. Rabinovici J, Blankstein J, Goldman B, et al. In vitro fertilization and primary embryonic cleavage are possible in 17 α-hydroxylase deficiency despite extremely low intrafollicular 17 β-estradiol. J Clin Endocrinol Metab. 1989;68:693-697.
62. Levy D, Navarro J, Schattman G, et al. The role of LH in ovarian stimulation. Hum Reprod. 2000;15:2258-2265.
63. Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod. 1991;6:1206-1212.